Global CRISPR Gene Editing Therapies Market 2026 – 2035

The CRISPR gene editing therapies market is projected to grow from USD 4.71 billion in 2026 to USD 18.96 billion by 2035 at a CAGR of 14.9% from 2026 to 2035.

Market Highlights

• North America was the biggest region in the CRISPR gene editing therapies market, accounting for nearly 48% in 2025.

• The fastest CAGR of 17.3% is expected for the Asia Pacific region, owing to the rapid growth of the number of CRISPR clinical trials in China (more than 80 registered CRISPR clinical trials in 2025).

• By type, ex vivo CRISPR therapies represented around 67% of the total market share in 2025.

• In vivo CRISPR therapies are the fastest-growing segment with a projected CAGR of 19.8% from 2026 to 2035.

• In 2025, the technology segment accounted for the highest share of the CRISPR-Cas9 market, with the share being about 54%.

• The genetic disorders were the key application accounting for around 44% of the application market in 2025 by application.

Impact of Middle East Conflict on the CRISPR Gene Editing Therapies Market

The Middle East conflict has had “indirect but meaningful” impacts on the CRISPR gene editing therapies market via several channels, most notably via a surge in oil prices, which has boosted the cost of operation of energy-hungry biomanufacturing facilities that are essential to the production of CRISPR therapies, such as controlled-environment cleanrooms, cryogenic storage systems, and cell therapy manufacturing platforms that require significant electrical power and specialty gas consumption.

Significant Growth Factors

Commercial Launch of First CRISPR Therapies Validating the Platform and Stimulating Broad Pipeline Investment

In December 2023, the FDA approved Casgevy (exagamglogene autotemcel, exa-cel) developed by Vertex Pharmaceuticals in collaboration with CRISPR Therapeutics for treating SCD and CRISPR Therapeutics’ own Lyfgenia (lovotibeglogene autotemcel) for treating TDT was also approved by the FDA. With these two drugs approved in the same month and Casgevy approved by the EMA in February 2024, this represented the most important regulatory success to date in the history of the field of CRISPR and the most powerful commercial endorsement of CRISPR as a therapeutic platform, bringing a significant boost of investment into CRISPR therapy development programs in the biotechnology and pharmaceutical industries.

With the potential for a single treatment using CRISPR to cure a severe genetic disease, such as replacing the need for chronic transfusion therapy, hospitalization for vaso-occlusive crisis, and disease management estimated at USD 1.7–4.4 million lifetime cost of treatment for sickle cell disease, there is a strong health economic reason for premium pricing.

The commercialization of Casgevy has driven unprecedented investment in CRISPR therapy companies, with global CRISPR therapy VC and corporate investment growing to around USD 4.8 billion in 2024, up 62% from the amounts invested prior to the approval of Casgevy. In early 2025, the global CRISPR clinical trial pipeline included around 190 active trials across hemoglobinopathies, oncology, inherited metabolic diseases, ophthalmology and infectious disease indications, the largest and most diverse clinical program portfolio of any gene editing platform, and a strong near-term clinical trial pipeline of potentially more additional CRISPR therapy approvals. The basic patent dispute over CRISPR-Cas9 technology has now been resolved, providing major clarity to the IP landscape around the development of CRISPR therapy.

Expanding CRISPR Application Pipeline Beyond Hemoglobinopathies Into High-Prevalence Diseases

The development of new indications beyond hemoglobinopathy (where the clinical and commercial case was built through Casgevy and Lyfgenia) – which encompasses a far larger commercial opportunity – is the key to the CRISPR therapy market's anticipated 14.9% CAGR, and the fundamental building blocks of the market's projected growth of approximately 5× between 2025 and 2035.

The oncology application, which covers the engineering of autologous CAR-T cell therapies with CRISPR-based improvements that include PD-1 knockout to reduce T-cell exhaustion, TCR disruption to enable allogeneic off-the-shelf CAR-T, and multi-gene editing to create stealth T-cells resistant to immune rejection, is the largest single commercial opportunity in the CRISPR therapy pipeline, with the world CAR-T cell therapy market estimated at ~USD 5.8 billion in 2024 and projected to reach ~USD 24.3 billion by 2035, with improvements based on CRISPR capturing an increasing percentage of total sales.

The most transformative area of the CRISPR oncology program is the development of allogeneic off-the-shelf CAR-T, where CRISPR editing of donor T-cells both disables the T-cell receptor (T cells would not reject the graft) and the CD52 gene (would not resist lymphodepletion conditioning) and also adds a CAR-T transgene, creating a standardized cell therapy product that can be manufactured at industrial scale and stored in cryogenic inventories for immediate infusion without the need for the 4-6 week personalized manufacturing process needed for autologous CAR-T, with Allogene Therapeutics, Precision BioSciences, and Intellia Therapeutics among the top developers of CRISPR-edited allogeneic cell therapy programs.

The application of CRISPR in the cardiovascular field is a commercially extraordinary opportunity in the in vivo liver targeted editing space, where the inactivation of the PCSK9 gene (which encodes the enzyme that degrades LDL receptors and is a proven target in cardiovascular risk reduction therapy, as evidenced by the marketed PCSK9 antibody inhibitors evolocumab and alirocumab) would provide the promise of an LDL cholesterol-decreasing therapy that would take just one injection and last a lifetime – for the estimated 250 million people with familial hypercholesterolemia or established cardiovascular disease who are now on lifetime statins and PCSK9 antibody therapy.

What are the Major Advances Changing the CRISPR Gene Editing Therapies Market Today?

Base Editing and Prime Editing Technologies Addressing CRISPR-Cas9 Precision and Safety Limitations

Pioneered by David Liu's lab at the Broad Institute and commercialized by Beam Therapeutics and Prime Medicine, respectively, the development of the base and prime editing platforms is the biggest leap in CRISPR technology since the original CRISPR-Cas9 platform, which has faced the two most significant limitations in CRISPR-Cas9 gene editing when applied at high precision in clinical settings: the ability to generate potentially mutagenic double-strand DNA breaks (DSBs) and dependence on error-prone non-homologous end joining (NHEJ) repair pathways that result in insertions or deletions at the editing site.

Base editing systems rely on a catalytically impaired Cas9 nickase that is fused to a DNA base deaminase enzyme that will precisely correct a single-nucleotide pathogenic point mutation without creating double-strand breaks in the genome, and with frequencies of off-target editing in human cell studies estimated to be 10-100 fold lower than equivalent CRISPR-Cas9 editing within the same genome. As of early 2025, there were about 12 active global base editing therapy programs in clinical trials, including Verve Therapeutics' liver-targeted base editing program, VERVE-101, for the prevention of cardiovascular disease, which showed reductions in LDL cholesterol of around 48% after a single injection in early Phase 1 data, BEAM Therapeutics' BEAM-101 for sickle cell disease with promising early clinical data, and the cardiovascular base editing program BEAM-301 for glycogen storage disease type Ia progressing toward clinical initiation.

Theoretically, prime editing is the most versatile and precise gene editing approach, with the ability to correct nearly 89% of all known pathogenic human genetic variants, compared to approximately 30% accessible by base editing, but it has additional delivery obstacles as the prime editing guide RNA (pegRNA) and prime editing cargo are larger than base editing and must be delivered as split intein-reconstituted or mRNA-LNP cargo. Prime Medicine, the lead prime editing therapeutic developer, is progressing its first two clinical programs in chronic granulomatous disease and alpha-1 antitrypsin deficiency to IND enlightenment, with the modular prime editing platform potentially targeting the ~6,200 rare genetic diseases caused by point mutations, small insertions, or deletions, of which ~7,000 are known.

Lipid Nanoparticle Delivery System Optimization Enabling Hepatic and Extrahepatic In Vivo CRISPR Delivery

The optimization of lipid nanoparticle (LNP) delivery systems for in vivo delivery of CRISPR therapies — built upon the LNP technology used in the BNT162b2 and mRNA-1273 COVID-19 mRNA vaccines that together proved the safety and scalability of LNP-mediated delivery of nucleic acids to hundreds of millions of people in vivo — is enabling the next generation of in vivo CRISPR therapy programs to target hepatic and increasingly extrahepatic tissues with delivery efficiencies and safety profiles that are nearing the clinical and regulatory threshold for broad therapeutic deployment.

In Phase 1 data published in 2022, Intellia Therapeutics' NTLA-2001, a CRISPR-LNP in vivo therapy targeting the TTR gene for transthyretin amyloidosis, showed durable reductions in the levels of the TTR protein at 12 months after a single dose, with approximately 93% of the reduction achieved, the first in vivo CRISPR editor to demonstrate durable editing in human patients, representing the first clinical demonstration of durable in vivo CRISPR editing in humans and establishing the proof of concept for a new class of in vivo genetic medicines that has since attracted substantial investment and competitive program development activity.

Category Wise Insights

By Type

Why Do Ex Vivo CRISPR Therapies Lead the Market?

The ex vivo CRISPR therapies will account for about 67% of total market revenue in 2025, a strong position due to the technical and regulatory maturity advantage of the cell editing paradigm behind the two ex vivo CRISPR therapies currently approved for commercialization (Casgevy and Lyfgenia), which involve editing patient-derived HSPCs ex vivo in order to achieve durable correction of the underlying genetic defect for sickle cell disease and beta-thalassemia patients, respectively, without direct systemic delivery of CRISPR parts to the patient.

Compared to in vivo delivery, the ex vivo approach offers multiple technically important advantages: The efficiency and off-target editing profile of the CRISPR editing reaction can be thoroughly characterized in the manufactured product prior to patient delivery; edited cells can be subjected to comprehensive quality release testing including karyotyping, assessment of insertional oncogenesis, and viability characterization before infusion into the patient; the concentration of guide RNA, delivery method of the Cas9, and duration of the edit reaction can all be optimized for maximal on-target activity and minimal off-target activity in the controlled laboratory setting.

By Technology

Why Does CRISPR-Cas9 Lead the Technology Segment?

CRISPR-Cas9 provides roughly 54% of the overall revenue from the technology segment in 2025 and is responsible for the majority of the approximately 190 active CRISPR clinical trials to date (as of early 2025), as well as commercially approved CRISPR therapies. Streptococcus pyogenes Cas9 (SpCas9), the most commonly used CRISPR-Cas9, is a protein that is capable of recognizing NGG protospacer adjacent motif (PAM) sequences found roughly every 8 base pairs in the human genome, has published safety data from clinical programs, and exhibits well-described biochemical behavior, all of which are advantages for new program initiation.

Amino acid substitutions to decrease non-specific DNA contacts and to increase the specificity toward discrimination between on- and off-target sequences have created high-fidelity variants of SpCas9, which have shown 10–100× lower frequencies of off-target editing compared to wild-type SpCas9 in human cell experiments without compromising on-target editing efficiency and which are increasingly replacing wildtype SpCas9 in new clinical program designs.

By Application

Why Do Genetic Disorders Lead the Application Segment?

The high proportion of market revenue for genetic disorders (c. 44 % in 2025) is driven by both the medical logic behind CRISPR therapy as a one-off genomic correction of a disease-causing mutation in patients with severe monogenic diseases which are unmet medical needs that cannot be addressed by conventional pharmacotherapy and the regulatory precedent set by the approval of Casgevy in two hemoglobinopathy indications.

With approximately 80% of the identified rare diseases having a genetic basis, the global population of patients with rare diseases is estimated at ~400 million people with ~7,000 known diseases, and the near-term clinical program priority is determined by the disease severity, gene therapy target validation, patient population size, competitive landscape, and manufacturing feasibility criteria, which collectively prioritize hemoglobinopathies, muscular dystrophies and inherited liver metabolic diseases.

By Delivery Mechanism

Why Do Viral Vectors Lead the Delivery Mechanism Segment?

In 2025, the viral vectors segment will remain dominant, representing about 48% of the revenue for delivery mechanism, with established clinical experience in the ex vivo manufacture of CRISPR cell therapies via lentiviral vectors and in vivo gene delivery via AAV vectors that inform and precede in vivo gene delivery CRISPR programs in the fields of ophthalmology, neurology, and metabolic disease. The global lentiviral vector CDMO market is projected to reach around USD 1.2 billion in 2024 and be expanded by around 14.8% CAGR.

Lentiviral vectors which can integrate into the host cell genome and deliver permanent transgene expression are the major delivery vehicles for ex vivo CAR-T manufacturing. Lipid nanoparticles are the fastest-growing delivery mechanism at 24.6% CAGR, and are gaining significant traction due to the safety validation of this technology with the deployment of COVID-19 vaccines, the technical versatility of LNP formulations to deliver mRNA-encoded Cas9 or base editors alongside chemically modified guide RNAs and the hepatic targeting efficiency that makes LNP-delivered CRISPR the preferred approach to the large, commercially attractive liver disease indication space, including transthyretin amyloidosis, PCSK9 targeting and alpha-1 antitrypsin deficiency.

Report Scope

Regional Analysis

How Big is the North American CRISPR Gene Editing Therapies Market Size?

The North American CRISPR gene editing therapies market is expected to be valued at nearly USD 8.76 billion by 2035, expanding at a CAGR of 16.8% during the forecast period from 2026 to 2035.

Why Did North America Dominate the Market in 2025?

This is driven by the presence of approximately 48% of the global CRISPR gene editing therapies market revenue share in North America, which is supported by the United States emerging as the leading commercial launch market for CRISPR therapeutics, as well as the highest number of CRISPR therapy biotechnology companies, including CRISPR Therapeutics, Intellia Therapeutics, Editas Medicine, Beam Therapeutics, Caribou Biosciences, and Verve Therapeutics, and advanced CRISPR therapy reimbursement infrastructure, such as the Centers for Medicare and Medicaid Services (CMS) exploring novel payment models, particularly installment payment arrangements focused on outcomes for high-cost gene therapies, which are also approved here.

Why is Europe the Second-Largest Market With Advanced Regulatory and Scientific Leadership?

The European Union was the second largest market to receive a CRISPR gene editing therapy endorsement in February 2024 with the conditional marketing authorization of Casgevy for sickle cell disease and transfusion-dependent beta-thalassemia and has also historically hosted the highest number of world-leading CRISPR scientific institutions, such as the Helmholtz Zentrum München, Wellcome Sanger Institute, Institut Curie, and Karolinska Institutet, which maintain European scientific leadership in CRISPR technology development.

Why is Asia Pacific the Fastest-Growing Regional Market?

Thanks to the remarkable rate of clinical trials using the CRISPR technique in China, the regulatory advancement in Japan that paves the way for faster CRISPR therapy approval, and the growing gene therapy manufacturing infrastructure in the region, Asia Pacific is expected to see the highest regional CAGR of 17.3% for CRISPR gene editing therapies market revenue from 2026 to 2035, accounting for approximately 18% of the global total in 2025.

Why is LAMEA an Emerging CRISPR Gene Editing Therapy Market With High Disease Burden Drivers?

In the coming years, LAMEA is expected to see a CAGR of 13.2% for CRISPR gene editing therapies market revenue, owing to a high prevalence of hemoglobinopathies among Middle Eastern and African populations, the vision of the Gulf Cooperation Council countries for healthcare investments, and the growing gene therapy research and clinical infrastructure in Brazil, which adds to the unmet medical need for a curative therapy.

Top Players in the Market and Their Offerings

• CRISPR Therapeutics AG

• Vertex Pharmaceuticals Incorporated

• Intellia Therapeutics Inc.

• Editas Medicine Inc.

• Beam Therapeutics Inc.

• Prime Medicine Inc.

• Caribou Biosciences Inc.

• Allogene Therapeutics Inc.

• Verve Therapeutics Inc.

• Precision BioSciences Inc.

• Others

Key Developments

The CRISPR gene editing therapies market has seen significant changes with top companies making strides in their next-generation therapy programs, scaling up capacity, and obtaining regulatory clearances in key markets.

• In March 2025: Intellia Therapeutics announced positive Phase 3 interim data from its in vivo CRISPR-LNP therapy targeting the KLKB1 gene for hereditary angioedema (HAE) that met the primary endpoint, with a mean 95% reduction in the rate of HAE attacks at 6 months after a single infusion of the therapy, a milestone that could mark the first approval of an in vivo CRISPR-based therapy if achieved, representing a turning point in the evolution of CRISPR-based therapy from ex vivo cell editing to the broader opportunity of in vivo genomic medicine.

• In January 2025: Beam Therapeutics signed the largest single base editing licensing deal to date with Pfizer in January 2025, valued at up to USD 1.05 billion, which includes USD 300 million upfront for developing base editing therapies in three undisclosed rare disease indications and in which Pfizer has received co-development and co-commercialization rights to the base editing therapeutics programs.

The strategic moves mirror the evolution of CRISPR therapy from a research curiosity to a commercial pharmaceutical reality that has seen billion-dollar investments from established pharmaceutical companies in CRISPR platform access, the first commercial CRISPR therapies see real-world clinical experience and the next generation of in vivo and base editing programs advance through pivotal clinical trials to regulatory submissions that will dramatically expand the commercially addressable CRISPR therapy indication space throughout the forecast period.

The CRISPR Gene Editing Therapies Market is segmented as follows:

By Type

• Ex Vivo CRISPR Therapies

  • Autologous Ex Vivo CRISPR Cell Therapies

  • Allogeneic Off-the-Shelf CRISPR Cell Therapies

  • CRISPR-Edited Hematopoietic Stem Cell Therapies

  • CRISPR-Edited CAR-T Cell Therapies

• In Vivo CRISPR Therapies

  • Systemic In Vivo CRISPR Therapies (LNP-delivered)

  • Locally Administered In Vivo CRISPR Therapies (AAV-delivered)

  • In Vivo Base Editing Therapies

  • In Vivo Prime Editing Therapies

By Technology

• CRISPR-Cas9

  • Wildtype SpCas9-Based Therapies

  • High-Fidelity Cas9 Variants (eSpCas9, HiFi Cas9)

  • Compact Cas9 Orthologs (SaCas9, CjCas9)

• CRISPR-Cas12

  • Cas12a (Cpf1)-Based Therapies

  • Cas12b-Based Systems

• CRISPR-Cas13

  • RNA-Targeting Cas13-Based Therapies

  • Cas13-Based Diagnostics & Therapeutic Hybrids

• Base Editing

  • Adenine Base Editors (ABE)

  • Cytosine Base Editors (CBE)

  • Dual Base Editors

• Prime Editing

  • PE2 and PE3 Prime Editing Systems

  • Epigenome Editing via Prime Editing

• Other Technologies

  • Epigenome Editing (CRISPRa/CRISPRi)

  • CRISPR-Associated Transposons (CAST)

  • Paired Nickase Systems

By Application

• Genetic Disorders

  • Hemoglobinopathies (Sickle Cell Disease & Beta-Thalassemia)

  • Duchenne Muscular Dystrophy (DMD)

  • Familial Hypercholesterolemia

  • Alpha-1 Antitrypsin Deficiency

  • Transthyretin Amyloidosis (ATTR)

  • Cystic Fibrosis

  • Other Rare Genetic Disorders

• Oncology

  • Hematological Malignancies (AML, ALL, Multiple Myeloma)

  • Solid Tumors (Lung, Liver, Pancreatic Cancer)

  • CRISPR-Enhanced CAR-T Therapies

  • CRISPR-Enabled Neoantigen Therapies

• Infectious Diseases

  • HIV/AIDS CRISPR Eradication Programs

  • Hepatitis B Virus (HBV) Functional Cure

  • HPV-Associated Disease

  • Emerging Viral Disease Programs

• Ophthalmology

  • Leber Congenital Amaurosis (LCA10)

  • Usher Syndrome

  • Age-Related Macular Degeneration (AMD)

• Cardiovascular Diseases

  • PCSK9 Inactivation for LDL Reduction

  • Angiopoietin-Like Protein 3 (ANGPTL3) Editing

  • Lipoprotein(a) Reduction Programs

• Other Applications

  • Central Nervous System Disorders

  • Autoimmune & Inflammatory Diseases

  • Metabolic Liver Diseases

By Delivery Mechanism

• Viral Vectors

  • Adeno-Associated Virus (AAV) Vectors

  • Lentiviral Vectors

  • Adenoviral Vectors

• Lipid Nanoparticles (LNP)

  • Ionizable LNP Systems

  • Organ-Selective LNP (SORT Technology)

  • PEGylated LNP Formulations

• Ribonucleoproteins (RNP)

  • Electroporation-Mediated RNP Delivery

  • Cell-Penetrating Peptide-RNP Conjugates

• Other Delivery Mechanisms

  • Extracellular Vesicles & Exosomes

  • Polymeric Nanoparticles

  • Hydrodynamic Delivery

By End Use

• Hospitals & Specialty Clinics

  • Authorized Treatment Centers (ATCs) for Approved CRISPR Therapies

  • Hematology & Oncology Specialty Centers

  • Rare Disease & Metabolic Disease Centers

• Academic & Research Institutions

  • University Research Laboratories

  • Government-Funded Research Institutes

  • Clinical Research Organizations (CROs)

• Biotechnology & Pharmaceutical Companies

  • Dedicated CRISPR Therapy Biotechs

  • Big Pharma CRISPR Licensing & Co-Development Programs

  • Gene Therapy CDMOs

• Other End Users

  • Patient Advocacy & Compassionate Use Programs

  • Agricultural & Industrial CRISPR Applications

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America